A number of BCMA targeted therapies have been introduced for relapse refractory multiple myeloma including—(1) CART therapy (Idecabtagene vicleucel and Ciltacabtagene autoleucel), (2) antibody drug conjugate (Belantamab mafodotin), and (3) bispecific antibodies (Teclistamab) [9]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.